T. Grombacher

发表

p53 is involved in regulation of the DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) by DNA damaging agents

B. Kaina, U. Eichhorn, T. Grombacher, 1998, Oncogene.

Regulation of expression of the DNA repair gene O6-methylguanine-DNA methyltransferase via protein kinase C-mediated signaling.

C. Ramana, B. Kaina, S. Mitra, 1998, Cancer research.

pdxBlacklist: Identifying artefactual variants in patient-derived xenograft samples

M. Salm, Sven-Eric Schelhorn, L. Lancashire, 2017, bioRxiv.

Isolation and analysis of inducibility of the rat N-methylpurine-DNA glycosylase promoter.

B. Kaina, T. Grombacher, 1996, DNA and cell biology.

Constitutive expression and inducibility of O6-methylguanine-DNA methyltransferase and N-methylpurine-DNA glycosylase in rat liver cells exhibiting different status of differentiation.

B. Kaina, T. Grombacher, 1995, Biochimica et biophysica acta.

Inducible Responses and Protective Functions of Mammalian Cells Upon Exposure to UV Light and Ionizing Radiation

S. Haas, B. Kaina, S. Mitra, 1999 .

Induction of the alkyltransferase (MGMT) gene by DNA damaging agents and the glucocorticoid dexamethasone and comparison with the response of base excision repair genes.

B. Kaina, S. Mitra, T. Grombacher, 1996, Carcinogenesis.

MCT-21-0934 859..870

L. Vassilev, B. Blume, T. Fuchss, 2022 .

RosettaSX: Reliable gene expression signature scoring of cancer models and patients

Sven-Eric Schelhorn, B. Brors, E. Staub, 2021, Neoplasia.

Combining Global and Local Measures for Structure-Based Druggability Predictions

Daniel Kuhn, Matthias Rarey, Friedrich Rippmann, 2012, J. Chem. Inf. Model..

Analyzing the Topology of Active Sites: On the Prediction of Pockets and Subpockets

Matthias Rarey, Andrea Volkamer, Thomas Grombacher, 2010, J. Chem. Inf. Model..

Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer

A. Tutt, R. Plummer, G. Shapiro, 2022, NPJ breast cancer.

Evolution of DNA Repair Mechanisms

B. Kaina, G. Obe, T. Grombacher, 2002 .

Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models

L. Vassilev, V. Kirkin, T. Fuchss, 2020, Molecular Cancer Therapeutics.

Transgenic systems in studies on genotoxicity of alkylating agents: critical lesions, thresholds and defense mechanisms.

S. Haas, B. Kaina, P. Lund, 1998, Mutation research.

Overexpression of cDNA encoding FANCC, SPHAR, MPG, SNM1 or HA 3611 does not render CHO cells more resistant to DNA crosslinking agents.

M. Tomicic, B. Kaina, M. Digweed, 1999, Anticancer research.

Abstract CT271: Translational analyses of ATR inhibitor M1774 in a Phase I study in patients with solid tumors (DDRiver Solid Tumors 301)

R. Plummer, A. Tolcher, T. Yap, 2023, Cancer Research.

A New Class of Selective ATM Inhibitors as Combination Partners of DNA Double-Strand Break Inducing Cancer Therapies

L. Vassilev, B. Blume, T. Fuchss, 2022, Molecular cancer therapeutics.

Where are the boundaries? Automated pocket detection for druggability studies

Matthias Rarey, Andrea Volkamer, Thomas Grombacher, 2010, J. Cheminformatics.

Abstract 4183: A novel selective DNA-PK inhibitor, M3814, as a potential combination partner of Etoposide and Cisplatin in the therapy of lung cancer

L. Vassilev, L. Damstrup, A. Blaukat, 2017 .

Implementation of whole-exome sequencing for pharmacogenomics profiling and exploring its potential clinical utilities.

J. Bolleddula, T. Grombacher, J. Scheuenpflug, 2024, Pharmacogenomics.

Mapping combinatorial drug effects to DNA damage response kinase inhibitors

Y. Guan, Sven-Eric Schelhorn, Hanrui Zhang, 2023, Nature communications.